These emerging therapies , Semaglutide , represent a groundbreaking advancement in treating obesity and possibly associated ailments . These drugs are categorized as GLP-1 pathway activators , meaning they to replicate the natural GLP-1 hormone , boosting metabolic release and suppressing appetit